New therapy aims to tackle emotional toll of type 1 diabetes
NCT ID NCT04933851
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a psychological therapy program called ACT1VATE to standard diabetes education in 250 adults with type 1 diabetes who have high emotional distress and poor blood sugar control. The therapy is delivered in five group sessions via video call. Researchers will measure changes in blood sugar levels and diabetes-related distress over 12 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Acceptance and Commitment Therapy (ACT)-based group telemedicine sessions
- What this could lead to
- If successful, this could provide an effective way to reduce diabetes-related emotional distress and improve blood sugar control in adults with type 1 diabetes.
- What could go wrong
- This is a Phase 2 trial with 250 participants, so results are still preliminary. The intervention is behavioral, so benefits may vary widely between individuals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2021
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Spanish or English-speaking * Type 1 diabetes * Glycosylated Hemoglobin (HbA1c) 7.0% - 12.5% in last 90 days * Screen positive for diabetes distress Exclusion Criteria: * Severe medical or psychological conditions that would interfere with participation based on the opinion of a provider * Plans to move out of the San Diego area in the next 12 months * Lack of technology capability required to complete online surveys and telemedicine visit
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Scripps Whittier Diabetes Institute
RECRUITINGSan Diego, California, 92121, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Can a math model tune insulin pumps better than standard care?
- Can a group program stop eating disorders in type 1 diabetes?
- Can a Two-Punch immune therapy save insulin cells in newly diagnosed diabetes?
- Can a smart insulin pump tailored for pregnancy protect mothers and babies?
- Can an automated pancreas system make type 1 diabetes safer in the real world?